On Thursday, Ligand Pharmaceuticals got a positive adjustment to its Relative Strength (RS) Rating, from 79 to 84.
Looking For The Best Stocks To Buy And Watch? Start Here
This exclusive rating from Investor's Business Daily tracks price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains typically have an 80 or higher RS Rating in the early stages of their moves.
Ligand Pharmaceuticals is not currently offering a proper buying opportunity. See if the stock goes on to build a base that could launch a new move.
The company showed -65% EPS growth last quarter. Sales rose 46%. The next quarterly numbers are expected on or around Aug. 7.
Ligand Pharmaceuticals earns the No. 11 rank among its peers in the Medical-Biomed/Biotech industry group. Incyte, TG Therapeutics and Gilead Sciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
